{"ok":true,"trend":{"id":250062,"platform":"news","region":"global","key":"kodiak sciences up 150% at opening bell after drugs pass key trial","title":"Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial","url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWkRCRmUxRW5SNnlEcDZBVUhKeGUyQkMtdS1CYmt2bWVEOU1WZ1l3NEhJVXoyc2YyQUUtMWVJNzhIejRqTWNCeU1ldVBUQVhIS05aV1R2UlNvN0hSYlJMbDMwaUF0MEdGV2E0UHAtSDZMeW9aV0ViQUNNNkplQjRqVnozd3VBUklkT3lCaXpMeFpkZWxQY2lZdEt0LUlVVUs0SnpTbDZHc2tMN1NFa2U5ZUdsc1FzYXFyVzFJN09PMA?oc=5","first_seen":"2026-09-28T15:52:52.710684Z","last_seen":"2026-09-28T22:42:52.373596Z","last_rank":31,"peak_rank":15,"last_volume":null,"peak_volume":0,"seen_count":6,"score":29.0,"category_hint":"science","section":"science","category":"science","summary":"Kodiak Sciences shares jumped roughly 150% at the opening bell after the biotech's drug passed a key clinical trial. The strong trial results triggered a sharp rally in the stock, making the eye-disease drug developer one of the day's biggest gainers and drawing investor attention to its pipeline prospects.","why":"Positive clinical trial results caused a dramatic single-day surge in the company's stock.","tone":"positive","entities":["Kodiak Sciences"],"summarized_at":"2026-09-28T21:57:01.640377Z","meta":{"via":"scan","lang":"en","term":"science","source":"Forbes","generic":0.05,"published":"Mon, 28 Sep 2026 13:50:46 GMT"},"nw":0.76,"promo":0.02,"kind":"news_event","importance":1.56,"hidden":false,"hide_reason":null,"judged_at":"2026-09-28T15:53:02.642441Z","title_en":"Kodiak Sciences Soars 150% After Drug Trial Success","section_name":"Science","category_name":"Science","timeline":[{"captured_at":"2026-09-28T15:52:52.710684Z","rank":15,"volume":null},{"captured_at":"2026-09-28T17:14:53.472958Z","rank":21,"volume":null},{"captured_at":"2026-09-28T18:36:53.660107Z","rank":19,"volume":null},{"captured_at":"2026-09-28T19:58:53.758661Z","rank":21,"volume":null},{"captured_at":"2026-09-28T21:20:53.414494Z","rank":18,"volume":null},{"captured_at":"2026-09-28T22:42:52.373596Z","rank":31,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWkRCRmUxRW5SNnlEcDZBVUhKeGUyQkMtdS1CYmt2bWVEOU1WZ1l3NEhJVXoyc2YyQUUtMWVJNzhIejRqTWNCeU1ldVBUQVhIS05aV1R2UlNvN0hSYlJMbDMwaUF0MEdGV2E0UHAtSDZMeW9aV0ViQUNNNkplQjRqVnozd3VBUklkT3lCaXpMeFpkZWxQY2lZdEt0LUlVVUs0SnpTbDZHc2tMN1NFa2U5ZUdsc1FzYXFyVzFJN09PMA?oc=5","author":"Forbes","title":"Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial","snippet":null,"posted_at":"2026-09-28T13:50:46Z","likes":null}],"elsewhere":[],"window":"7d"}}